Hot Topics and Issues in the Biosimilars Space: Part One
February 29, 2016

Axinn sponsored the New York Intellectual Property Law Association panel, "Hot Topics and Issues in the Biosimilars Space." Co-hosted with NYIPLA's Women in IP Law Committee, the panelists - including Axinn partner Chad Landmon - discussed recent case law and provided commentary from both the brand and biosimilar perspective on future application of the BPCIA. Regulatory issues, FDA strategy and the pros and cons of using IPRs on patents involving biologics were also addressed.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.